A note for historians: On April 21, 2026, pancreatic cancer finally began to budge.
Cancer immunotherapies have transformed treatment for many cancers, but pancreatic cancer remains especially difficult to treat.
Pancreatic cancer finally starts to budge as daraxonrasib doubles overall survival
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
YOU MAY BE INTERESTED IN
LSU Health New Orleans received a five-year, $3.1 million NIH grant to support pancreatic cancer research led by investigators in the LSU LCMC Health Cancer Center.
Researchers at the Johns Hopkins Kimmel Cancer Center and its Skip Viragh Center for Pancreatic Cancer have reported that an experimental vaccine targeting mutant KRAS, one of the most common genetic drivers of pancreatic cancer, was safe and generated durable immune responses aimed at preventing the cancer in people at high risk.
Zoldonrasib, an oral RAS(ON) G12D-selective covalent inhibitor, in combination with daraxonrasib showed 81% objective response rate compared to zoldonrasib in combination with standard of care chemotherapy in previously untreated patients with RAS G12D metastatic pancreatic ductal adenocarcinoma, according to results of two phase I/II study.
A “tumor-on-a-chip” model is giving scientists a live look at how pancreatic cancer can recruit the body’s own immune cells to help tumors survive. The study reveals possible new targets to weaken the cancer’s defenses and make treatments work better.
When Robert Mayer was only a few years out of residency, in the 1970s, he signed on as an investigator of the NCI-supported Gastrointestinal Tumor Study Group, which conducted research into colorectal, gastric, and pancreatic cancers.
